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Acrolein is produced endogenously after traumatic brain injury (TBI) and is 
considered a primary mechanism for secondary damage occurring after TBI. We are 
using frontal cortex networks derived from mouse embryos and grown on 
microelectrode arrays in vitro to monitor the spontaneous activity of networks and the 
changes that occur after acrolein application. Networks exposed to acrolein exhibit a 
biphasic response profile. An initial increase in network activity, followed by a decrease 
to 100% activity loss in applications ≥ 50 µM. In applications below 50 µM, acrolein was 
not toxic but generated activity instability with coordinated but irregular population busts 
lasting for up to 6 days. The increase in activity preceding toxicity may be linked to a 
decrease in free spermine, a free radical scavenger that modulates Na+, K+, Ca+ 
channels as well as NMDA, Kainate, and AMPA receptors. Action potential wave shape 
analysis after 20 and 30 µM acrolein application revealed a concentration-dependent 
15-33% increase in peak to peak amplitude within minutes after exposure.  For the 
same concentrations of acrolein (50 µM), the time required to reach 100% activity loss 
(IT100) was longer in serum-free medium than in medium with 5% serum, in which IT100 
values were reduced by a factor of 4.  The greater toxicity in the presence of serum may 
be explained by acrolein adducts on serum proteins. These reaction products have 
been shown by other labs to be toxic in cell culture. This in vitro system could be used 
to expand biochemical analyses such as acrolein-induced spermine depletion and may 
 









TABLE OF CONTENTS 
Page 
LIST OF TABLES ............................................................................................................ v 
 
LIST OF FIGURES ..........................................................................................................vi 
 
CHAPTER 1. INTRODUCTION ....................................................................................... 1 
1.1 Significance in Neurophysiology ................................................................ 2 
 
CHAPTER 2. METHODS ................................................................................................ 6 
2.1 Microelectrode Array (MEA) Fabrication .................................................... 6 
2.2 Frontal Cortex Cell Culture ........................................................................ 7 
2.3 Selection of a Network for Experimentation ............................................... 8 
2.4 Electrophysiological Monitoring ................................................................. 8 
2.5 Methods for Analysis of Electrophysiological Data .................................. 11 
2.6 Acrolein Storage, Preparation, and Administration .................................. 12 
 
CHAPTER 3. RESULTS ................................................................................................ 15 
3.1 Acrolein Diethyl Acetate (ADA) ................................................................ 15 
3.1.1 ADA Response Profiles ................................................................. 16 
3.1.2 ADA Dose Responses .................................................................. 20 
3.1.3 Morphological Responses ............................................................. 21 
3.2 Acrolein Stabilized in 10% Hydroquinone (AHQ) ..................................... 22 
3.2.1 AHQ Dose Response .................................................................... 22 
3.2.2 Changes in Network Spike Patterns .............................................. 24 
3.2.3 Morphology ................................................................................... 27 
3.3 Hydroquinone (HQ) .................................................................................. 28 
3.3.1 Responses to Low HQ Concentrations ......................................... 29 
3.3.2 Dose Response Curves ................................................................ 31 
3.4 Analytical Acrolein (AA) ........................................................................... 32 
3.4.1 Network Response Profiles ........................................................... 32 
3.4.2 Spike Production and Pattern Changes ........................................ 35 
3.4.3 Waveshape Analysis ..................................................................... 38 




CHAPTER 4. DISCUSSION .......................................................................................... 41 
4.1 Acrolein .................................................................................................... 41 
4.2 Hydroquinone .......................................................................................... 44 
4.3 Conclusion ............................................................................................... 44 
 
APPENDIX A. DEFINITIONS AND ACRONYMS .......................................................... 46 
 
APPENDIX B. SOLUTION SOURCE CONCENTRATION CALCULATIONS ................ 49 
 





LIST OF TABLES 
Page 
Table 2.1. Globally Harmonized System (GHS) Hazard Classification of Acrolein ........ 12 
Table 2.2. Chemical and Toxic Properties of Acrolein ................................................... 13 
Table 2.3. Acrolein Solution Prep .................................................................................. 14 
Table 3.1. Table of ADA Experiments ........................................................................... 16 
Table 3.2. Acrolein HQ Experiments ............................................................................. 22 
Table 3.3. Table of HQ Experiments ............................................................................. 29 
Table 3.4. Table of Experiments with Analytical Acrolein .............................................. 32 





LIST OF FIGURES 
Page 
Fig. 2.1. Neuronal cells on a 64 electrode micro electrode array (MEA) ......................... 6 
Fig. 2.2. Electrophysiological and life support setup ..................................................... 10 
Fig. 2.3. Common displays of the Plexon Omniplex system. ......................................... 11 
Fig. 3.1. Network activity responses to single ADA applications are concentration and 
medium dependent........................................................................................................ 17 
Fig. 3.2. Log-log plot of the time until 100% activity decrease vs ADA concentration in 
serum-free medium) ...................................................................................................... 18 
Fig. 3.3. Change in network pattern after 50 mM ADA. Burst rate increases for 50 
minutes before decreasing from reference activity range. ............................................. 19 
Fig. 3.4. Dose response for ADA on a single culture disinhibited with 40 mM bicuculline
 ...................................................................................................................................... 20 
Fig. 3.5. Morphological responses to 50 mM ADA. (A) Directly after dose ..................... 21 
Fig. 3.6. Response in percent change of spike activity from reference after application of 
AHQ. ............................................................................................................................. 23 
Fig. 3.7. Decrease in spontaneous activity measured as percent of reference overtime 
for two 50 mM AHQ experiments: one in medium with serum and the other in serum free 
medium ......................................................................................................................... 24 
Fig. 3.8. Network spike production and patterns change after 60 mM AHQ ................... 25 
Fig. 3.9. A 1.1 mM AHQ application after 1.0 hr of stable reference spike activity ........ 26 
Fig. 3.10. Morphological responses to 50 mM AHQ application on a frontal cortex 
network .......................................................................................................................... 27 
Fig. 3.11. A 10 mM AHQ on a frontal cortex network .................................................... 28 
Fig. 3.12. Network changes to multiple additions of HQ ................................................ 30 
Fig. 3.13. Applications  ≥ 150 mM HQ show a decrease in spike rate ........................... 31 
Fig. 3.14. Dose response curve representing all hydroquinone experiments under 40 mM 
bicuculline (n=6) ............................................................................................................ 32 
vii 
 
Fig. 3.15. Network activity responses to single analytical acrolein applications in the mM 
range ............................................................................................................................. 33 
Fig. 3.16. Network activity responses to single analytical acrolein applications in the mM 
range ............................................................................................................................. 34 
Fig. 3.17. Dose response curve for analytical acrolein .................................................. 35 
Fig. 3.18. A 30 mM application of analytical acrolein to a network after 2.5 hr of stable 
reference activity ........................................................................................................... 36 
Fig. 3.19. A 0.5 mM analytical acrolein application after 2.5 hr of stable reference 
activity. .......................................................................................................................... 37 
Fig. 3.20. A 50 mM application of analytical acrolein to a spontaneously firing network  
 ...................................................................................................................................... 38 
Fig. 3.21. A 20 and 30 mM analytical acrolein application increases the action potential 
amplitude in minutes and continues to slowly increase over the first phase profile of 
analytical acrolein. ......................................................................................................... 39 
Fig. 3.22. All acrolein compounds used in results section prior are summated ............. 40 






Reactive aldehydes are a biomarker of oxidative stress, generated through 
several metabolic pathways (Cerevelli, 2004; Murray-Stuart, 2004; Wood, 2007). 
Acrolein is the most reactive aldehyde, and is a more potent toxicant than hydrogen 
peroxide in cell culture (Sharmine et al 2001). It catalyzes reactive oxygen species 
(ROS), possesses a half-life that is orders of magnitude greater than any known ROS, 
can continue self-propagation through initiation of lipid peroxidation and ROS formation, 
and is further generated by oxidase enzyme up-regulation (Ghilarducci et al., 1995). 
The presence of acrolein within a cell is followed by an ionic imbalance, ATP depletion, 
proteolysis and oxidative stress (Sullivan et al., 1998). Exogenous exposure to 
aldehydes or acrolein can induce oxidative stress and acrolein generation within tissues 
of all types (LoPachin & Gavin, 2014). 
In chemical structure, acrolein is the smallest aldehyde and is a strong 
electrophile, meaning it is electron deficient. This property makes acrolein seek an 
(electron rich) nucleophile to covalently bond via Michaels addition (Lopachin & Gavin, 
2014). Adducts of acrolein inactivate and impair enzymes, DNA, and structural proteins 
inhibiting cellular processes.  Mitochondria, thiol groups and cysteine amino acid 
residues are normal targets for acrolein adduction. Enzymes and co-factors are 
inhibited by acrolein adduction, leading to a mitochondrial permeability state and 
inhibition of ATP production. (Picklo, 2000; Lijuan, 2006; Tsutsu, 2014).  
Defense mechanisms exist for electrophilic compounds within the cell. 
Glutathione transferase is a group II CYP enzyme responsible for deactivation of 
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electrophilic chemicals. Glutathione is a strong nucleophile that readily conjugates with 
acrolein and undergoes N-acetylation to produce S-(3-oxopropyl)-N-acetylcysteine 
(OPMA).  Oxidation of this product to OPMA-S-oxide creates an even more toxic 
compound than acrolein (Stevens & Maier, 2008).   
 
 Significance in Neurophysiology 
 Acrolein is produced endogenously within neural tissue after traumatic brain 
injury (TBI) and is a biomarker for head or spinal injury (Tsutsui, 2014; Shi et al., 2015; 
Cebak et al., 2016). Acrolein and its aldehyde derivatives were found to be the primary 
mechanism for secondary damage that occurs weeks to months after a TBI, 
concussion, or surgical procedure on the spine (Cebak et al., 2016). This chemical is 
also found in high concentrations in neurodegenerative diseases (i.e. Alzheimer’s, 
Parkinson’s, multiple sclerosis, stroke and vascular ischemia).  
 There is an abundance of literature on the cytotoxic mechanisms of acrolein. 
Very little literature on the functional effects of acrolein on electrically excitable cells, 
such as neurons, exists within current literature. Now I will cover the known 
mechanisms by which acrolein can induce excitotoxicity, increasing secondary damage 
after the initial physical insult. 
There is a period of increased NMDA receptor activation and associated 
excitotoxicity after TBI, this lasts for only a few hours in a mouse model, and 1-2 days in 
a human model. This is followed by electrophysiological inhibition (Bullock et al., 1992; 
Biegon et al., 2004; Krishnamurthy et al., 2016). The same functional manifestations 
have been implicated in stroke and cerebral ischemia, where acrolein is also produced 
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endogenously. There is no current knowledge on the functional response of networks 
when exposed to acrolein in neural tissue. This response is life threatening and, in a 
laboratory setting, has value for developing innovative pharmacotherapy to treat 
secondary damage after sustaining a TBI. 
 Acrolein is generated by and catalyzes lipid peroxidation, also forming free 
radical reactions. Following a TBI, increased activity of amine oxidase (AO) and 
spermine oxidase (SO) produces excess acrolein as a byproduct of enzymatic catalysis 
(Tomitori, 2005; Caldwell, 2015). These enzymes are important in the production of 
polyamines. Polyamines are found in all human tissue systems, with the highest 
concentrations found in brain tissue. They play a regulatory role in the membrane 
potential and action potential production of neurons.  
 Spermine, a polyamine, modulates the N-methyl-D-aspartic acid (NMDA) 
receptor function as well as inwardly rectifying potassium channels (Zapia et al., 1980; 
Morris & Mayer, 1993; Tsutsui, 2014). Spermine also plays a regulatory role in sodium 
(Na+) channels; and its depletion has shown to increase spontaneous spiking and 
hyper-synchronized discharge in cortical neurons (Fleidervish et al., 2008). Spermine is 
present at a 2.0 mM concentration within the nucleus and is released during oxidative 
stress because it functions as a direct free radical scavenger (Ha et al., 1998). Tsutsui, 
2014 demonstrated: acrolein adducts to spermine and other polyamines via Michaels 
addition. The amine-acrolein adducts polymerize in favor the formation of 
diazacyclooctanes. The decrease in free spermine within a neuron would lead to an 
increase in spontaneous spiking and coordinated bursting, increasing NMDA activation, 
AO and SO activation, ROS formation and ultimately oxidative stress. 
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 The presence of NMDA receptor hyper-activation and excitotoxicity after a TBI in 
mice has been implicated along with the process of secondary damage (Beigon et al., 
2004, Krishnamurthy et al., 2016). Increased activation of NMDA receptors and 
excitotoxicity have been classified as key components to the pathophysiology of 
secondary damage after TBI (Yi & Hazell, 2006; Werner & Engelhard, 2007; Greve & 
Zink, 2009). The latest key component to secondary damage, the presence of acrolein, 
was published in 2016 (Cebak et al.).  Free radical scavengers were able to mitigate the 
typical degeneration seen post TBI (ibid). 
The increase in PO, ROS, and acrolein activates microglial cells which induce 
genetic changes in surrounding astrocytes (Patel, 2016). These changes create a 
pathogenic astrocyte, labeled A1, which alters transcription to inhibit the abilities of 
facilitating neuronal survival, outgrowth, synaptogenesis and phagocytosis (Liddelow, 
2017). The astrocytic glutamate transporter is down regulated in A1 astrocytes, leaving 
excess glutamate in the synapse (Yi & Hazell, 2006; Landgehem, 2006; Lin, 2012; 
Guerriero, 2015). This means that oxidative stress from increased activity could 
promote the further generation of acrolein, a self-catalyzing compound with the longest 
half-life of any ROS.  
Post TBI induced epilepsy is positively correlated with TBIs that include 
hemorrhaging. In the literature, a 24-hour window exists for treatment to avoid post TBI 
induced epilepsy and this is suggested by the death of important inhibitory interneurons 
(which are highly sensitive to oxidative stress) during TBI induced excitotoxicity 
(Sloviter, 2011).  Langer et al demonstrated in 2011 that treatment with a low affinity, 
noncompetitive NMDA antagonist in the first 24 hours after TBI reduced the death of 
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important inhibitory interneurons. This also reduced post TBI induced epilepsy (Langer 
et al., 2011). 
 The project represents an in vitro, exogenous exposure to acrolein in murine 
mouse frontal cortex neuronal networks for quantitative insight into the functional 
changes that occur in electrophysiology generation of acrolein. The biochemical nature 
already known about this compound in current literature reveals a possibility that 
acrolein can induce functional changes important in the process of secondary damage 
and degeneration following a physical insult. This study aims to elucidate the functional 
changes when acrolein is added to a neuronal network without any of the other 





Microelectrode Array (MEA) Fabrication 
All MEAs used in this study were fabricated in the Center for Network 
Neuroscience (CNNS) photolithography laboratory at the University of North Texas by 
undergraduate volunteers (Christopher Pino and Jake Gray). The MEA fabrication 
technique has been published in detail previously (Gross, 1979; Gross et al 1985; 
Gross, 1994). 
MEAs are 5 x 5 cm glass plates coated with of film of indium-tin oxide (ITO). 
Conductors are photoetched and then insulated with 2-3 mM thick polysiloxane resin 
(methyltrimethoxysilane). The electrodes are constructed by laser de-insulation which 
creates 20 mM diameter craters. The exposed ITO is coated with gold to decreased 
impedance. The center of the MEA has a 1.0 mm2 recording area comprised of 64 
microelectrode terminals. 




 Frontal Cortex Cell Culture 
 The frontal cortices of E16 mouse embryos are isolated in a sterile balanced salt 
solution, dextrose-1, sucrose, glucose, and HEPES buffer (D1SGH). This solution 
moistens and stabilizes the osmolarity of the tissue for mincing with surgical scalpels. 
The D1SGH is aspirated and replaced with 5.0 ml of 0.05% trypsin and 1.5% DNase II 
solution. The minced tissue is incubated for 13 minutes at 37 o C.  The entire solution is 
aspirated by pipette and replaced by 5.0 ml of Dulbecco’s modified Eagle medium 
(DMEM). Tissue is given 3.0-5.0 minute to settle at the bottom of the 15 ml centrifuge 
the medium is then aspirated and replaced by fresh DMEM. This new suspension is 
given 3.0-5.0 minutes to settle and then the medium is aspirated and replaced by 8.0 ml 
of DMEM. The tissue is triturated gently, 5.0-7.0 times, then sampled for cell count on 
the hemocytometer. Cell density is adjusted to 70,000 cell per 100 (700,000 cells per 
ml) using DMEM for dilution of cells. Cells are pipetted onto MEAs (previously coated in 
poly-D-Lysine and laminin), in a 100 µL volume and incubated at 38.0 o C in 10% CO2. 
After 1.0-2.0 hr for adhesion, cells receive a 3.0 ml volume of DMEM with 5.0-10% fetal 
bovine serum. Cells develop in this medium until the third day in vitro (DIV). At this 
point, the medium is exchanged with DMEM with 5% horse serum. Routine feeding is 
conducted biweekly. 
Once the glial carpet is 100% confluent, serum is decreased to 2% for control of 
glial cell growth. Networks are allowed 4 weeks to develop before experimentation. 
GABAa agonists and antagonists are used routinely to test pharmacological responses 
of cultured networks. 
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 Selection of a Network for Experimentation 
 Phase contrast microscopy is used to monitor network growth and development. 
When the network has fully developed (~ 4 weeks), selection is based upon a criterion 
that combines microscopy and laboratory equipment. This is necessary for time 
efficiency as well as experimental success. The criteria are based on several 
parameters. 
 The first criterion is morphology. Cytoplasmic membrane characteristics, cell 
density, density of processes connecting cells within the network, stressed or dying 
cells, activated glial cells and glial carpet density. 
 The second criterion is the network location. If the network adheres to a location 
off center from the MEA, no electrophysiological data can be obtained. This makes the 
culture a candidate for time lapsed microscopy experiments only. 
 The third criterion is the MEA condition. loss of gold increases the electrode 
impedance.  Cracks lower the shunt impedance, resulting in a loss of signal., 
 The fourth criterion is osmolarity. Sampling of 10 µL network medium inside the 
clean room is taken outside to be measured by the osmometer.  
 If a culture passes all four of these criteria, it is selected for experimental setup. 
Further selection methods are discussed in the next section, once electrophysiological 
data is available.   
 
 Electrophysiological Monitoring 
 MEAs with mature, monolayer networks have pharmacological histiotypic 
electrophysiological responses, like the parent tissue (Gross et al.,, 1993; Gross & 
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Gopal., 2006; Potter & DeMarse, 2001; Johnstone et al., 2010). Tissue is transferred 
from a Petri dish inside the incubator, into a chamber that functions as an external 
incubator while allowing for amplification of electronic signals. The chamber is opaque 
with a window for phase contrast microscopy, closed to external air with an ITO cap to 
minimize heat loss, dehydration, contamination and maintain constant life support 
conditions (osmolarity, pH and temperature).  The ITO window is heated to prevent 
condensation and allow microscopic observation during the entire experiment. 
 The chamber is placed on an inverted, phase contrast microscope to allow for 
simultaneously electrophysiological and morphological monitoring. Details on the 
experimental setup have been described previously (Gross and Schwalm, 1994; Gross 
et al., 1994). Cultures are kept at 37 o C with a within a range one of ± 1.0 o C. A 
continuous 10 ml/min stream of medical grade 10% CO2 in air flows into the chamber 
cap to maintain pH in the range of 7.3 to 7.5. The phenol red indicator of the stock 
media for pharmacology is used for qualitative measurement of pH for the duration of 
the experiment. Quantitative hydrogen ion concentrations from pH meters are used to 
accurately measure medium when a 100 µL volume is available for measurement.  
Osmolarity measurements require only a10 µL test volume and could be made 
through the course of the entire experiment. When measuring osmolarity, to control for 
sampling errors due to stratification, 50% of the medium is withdrawn temporarily from 
the chamber and a 10.0 µL volume is taken from this sample. 
 Two chambers were used for these studies: a single network M-4 chamber with 
two Luer ports and a total volume of 2 mL, and a dual network M-5 chamber with 
separate wells of 1 mL volume and two Luer ports each. In each case one port is used 
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for water addition from a syringe pump to compensate for evaporation and maintain 
osmolarities. The other Luer port is used for medium changes, extraction of medium 
samples and test substance application (Fig. 2.1).  
 Test substance application: 100-300 µL medium sample is withdrawn from the 
network chamber via the Luer port into a syringe. The syringe is withdrawn and the test 
substance is injected into the syringe tip by with a micropipette. The syringe with 
medium is inserted into the chamber Luer port where another small amount of medium 
is carefully withdrawn and mixed with the medium containing the test substance. The 
test substance and medium mixture is slowly returned into the network chamber.  
 
Fig. 2.2. Electrophysiological and life support setup: (Left) M4 chamber which records 
from a single network. 32 preamplifiers (Plexon Inc.) are attached to either side.  (Right) 
M5 chamber which allows for the recording of two separate networks, each in their own 
chemical environment. CNNS Archives. 
 
 The amplification is achieved in two stages. A 100-fold fixed amplification with 32 
preamplifiers positioned to the left and right of the chamber and a variable second stage 
amplifier that can adjust total amplification up to 20,000. Normal amplification levels are 
10,000 to 12,000. Spikes can be identified by wave shapes (wave shape template 
algorithm, Plexon inc Dallas). With good signal to noise ratios is possible to separate 
four wave shapes on one physical channel in real time (Fig. 2.3). Primary network 
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activity is displayed as real time spike raster display from wave shape crossings of a 
threshold with a resolution of 25 µsec. 
 An additional custom CNNS program (Vernac) plots total activity or average 
activity per min which allows visualization of changes in network activity. This is a 
convenient, simple display used for all experiments. 
 
Fig. 2.3. Common displays of the Plexon Omniplex system. (A)  Real time extracellular 
firing of each individual unit that has been selected. (64 channels).  (B): High signal to 
noise ratios (SNR) in a 32-channel recording system. Under these conditions, 
waveshape separation is possible with high precision and a maximum of 4.  
 
 Methods for Analysis of Electrophysiological Data 
Network spike production was plotted as mean or total spikes per minute for the 
entire experiment. Each minute, the total activity was divided by the active channels 
(floating average). An active channel was defined as one with at least 10 discriminated 




activity and represented the primary real time contact with the network. Burst activity 
was monitored with the Plexon raster display and quantified offline. 
Activity from different networks was never pooled, and changes were normalized 
as percent decreases from network-specific reference activity that was maintained in a 
stable state for a minimum of 60 min (native activity) before acrolein experiments. 
Neurophysiological parameters were quantified from spike rate plots using NEX 
analysis programs (NEX Technologies). All Plexon time stamps are stored with a 25 µs 
resolution and a raster plot of all channels can be re-created for the entire experiment.  
Segments of such data are used in several figures in this thesis to depict complex 
changes in activity.  Sigmoidal fits to dose-response data were obtained either with 
Excel XL Stat and with Origin V-7. 
Irreversible activity decreases were obtained at single concentrations and key 
values were expressed as IT100, i.e. the time when activity had decayed 100%. 
 
 Acrolein Storage, Preparation, and Administration 
Table 2.1. Globally Harmonized System (GHS) Hazard Classification of Acrolein 
 
Flammable liquids Category 2 
Acute Oral Toxicity Category 2 
Acute Inhalation Toxicity Category 1 
Acute Dermal Toxicity Category 2 
Skin Corrosion   Category 1B 
Serious Eye Damage Category 1 
Acute Aquatic Toxicity Category 1 




According to the University of California Berkley, it is standard operating 
procedure to wear gloves, a lab coat, ANSI-approved safety goggles, cotton based 
clothing and closed toe shoes. Work should take place under a laboratory type fume 
hood with sash position closed.  In order to comply with this, as well as ensure 
additional protection between fume hood and experiment, a carbon activated mask was 
an addition to this experiment’s standard operations. The CAL/OSHA permissible 
exposure limit (PEL) is 0.1 ppm (0.25mg/m3). 
 Acrolein storage: acrolein is an auto-ignitable auto-oxidant. It must be stored in a 
cool, dry, hypoxic environment to ensure its stability. Source acrolein bottle must be 
filled with nitrogen before being placed back into 4-8 o C. 
Table 2.2. Chemical and Toxic Properties of Acrolein 
Chemical formula C3H4O 
Molecular weight 56.06 g/mol 
Melting point/freezing 
point 
-87 o C (- 125 o F) 
Boiling point 52.2  o C (125.5 o F) 
Odor threshold 0.21 ppm 
Skin protection Handle with gloves, minimum 
thickness 0.3 mm 
Body protection A lab coat and sterile sleeves 
Respiratory protection Carbon activated gas mask 
USA. Occupational 
Exposure Limits 
(OSHA) - Limits for Air 
Contaminants  
0.10 ppm 0.250000 mg/m3 
 
ACGIH Threshold 




Each experiment required a new solution because of the instability and high 
reactivity of acrolein. Depending on the experimental concentration, either ultrapure 
H2O or DMEM stock solutions was used to dilute the source acrolein solution. Sterility 
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procedures are maintained between the source acrolein bottle (Sigma) and solution 
(DMEM or ultrapure H2O). 
Table 2.3. Acrolein Solution Prep 
Chemical Solvent(s) 40 mM Bicuculline 
(in Network Prior) 
Acrolein Diethyl Acetate 
(Stabilized in 4% 
Hydroquinone) (ADA) 
DMEM with 5% serum 
DMEM stock (serum free) 
yes 
Acrolein (stabilized in 10% 
Hydroquinone) AHQ 
DMEM stock (serum free) 
Ultrapure H2O 
yes 







The following results were obtained with a cell culture model that has shown 
utility for exploring the origins of spontaneous activity and study the internal dynamics of 
neuronal ensembles.  It has also found realistic applications to pharmacology and 
toxicology. This approach provides the unique ability to simultaneously record 
electrophysiological data derived from frontal cortex networks while observing the 
network morphology. This is not possible in any in vivo model system due to the 
biological complexity. Data is presented in 4 sections representing the 4 different 
chemicals tested: acrolein diethyl acetate (ADA), acrolein stabilized in hydroquinone 
(AHQ), analytical (pure) acrolein (AA), and hydroquinone (HQ). The latter substance 
was investigated to determine if it contributed to the toxicity seen in AHQ and ADA 
experiments because their use as a stabilizer. Each section will begin with a table of 
experiments, show electrophysiology responses, dose response curves, and conclude 
with microscopy. 
Acrolein Diethyl Acetate (ADA) 
Acrolein diethyl acetate is a similar, but larger and less volatile aldehyde in 
comparison to acrolein itself. It is stabilized in 4% HQ to prevent auto-oxidation of the 
compound. A protocol for a single application of ADA and utilizing the response variable 
of time was constructed in this process.   
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MA005 44 33 1.19.16 3.2.16 41 
MB005 88 27 1.19.16 3.2.16 41 
MA006 47.6 36 1.19.16 3.10.16 49 
MA004 7 37 1.19.16 2.24.16 28 
MA011 120 37 2.2.16 3.23.16 49 
MB011 240 22 2.2.16 3.23.16 49 
MA014 47 33 1.19.16 4.5.16 84 
MA008 12 23 2.2.16 3.15.16 42 
MA007 34 30 2.2.16 3.16.16 43 
MB007 34 5 2.2.16 3.16.16 43 
MA009 1 45 2.2.16 3.17.16 44 
MB009 1 32 2.2.16 3.17.16 44 
MB009B 1,000,000 32 2.2.16 3.17.16 44 
MA010 6 12 2.2.16 3.18.16 45 
MA012 30 0 2.2.16 3.28.16 55 
 
3.1.1 ADA Response Profiles 
Fig. 3.1 shows the reduction in spike activity from four different networks 
exposed to different concentrations of ADA.  Percent loss of activity is plotted against 
time on a linear scale.  In this case, a 50% loss is identified as an IT50.  Whereas the 
activity decrease is concentration dependent, with higher concentrations leading to a 
more rapid loss of activity, the effect of serum was unexpected and is paradoxical., The 
two experiments in serum-free medium take much longer to lose their activity.  Since 
serum is known to bind a variety of substances, therewith decreasing the effective 
concentration of the toxicant, it is generally observed that a serum-free environment 
offers less protection, leading to a more rapid decay of network activity.  This is not 
observed in these experiments and is presently without explanation. The IT50 of ADA in 
the presence of serum is 48 and 90 min for 88 and 44 mM ADA (Fig. 3.1). The IT50 of 
ADA in serum free medium was 225 and 300 min for 50 and 34 mM.  This is a 
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substantial shift, indicating an increased potency in the presence of biomolecules found 
in serum. 
 
Fig. 3.1. Network activity responses to single ADA applications are concentration and 
medium dependent. Linear plots with polynomial fitting show expected concentration-
dependence but paradoxical effects of serum-containing medium.  IT50 values at 44 
and 88 mM in serum are 90 and 50 min respectively.  In serum-free medium IT50 values 
at 30 and 50 mM are 300 and 235 min, respectively.  The insert amplifies the two 
response curves obtained in serum-containing medium. NOTE: serum-free responses 
were biphasic (not shown; ~10-20% increases for 50-100 min). 
 
 Fig. 3.2 plots the IT100 values for all ADA experiments with single applications 
(n=6).  In the range from 6 mM to 1 Molar, a log-log plot provides a linear function.  Two 
experiments received a full medium change :10 and 6 hr after ADA application.  These 
data points (see triangles) remain on the trend line, indicating that the toxicity of ADA is 






Fig. 3.2. Log-log plot of the time until 100% activity decrease vs ADA concentration in 
serum-free medium). Two experiments received a medium change: 10 min after 12 mM 
and 6 hr. after 7 mM ADA application (circled markers above).  However, spike 
termination does not deviate from the log-log function. These observations imply that 
the ADA effect is established very early after exposure and cannot be reversed by 
medium changes.  
 
 The raw data that has led to the graphs shown in Fig. 3.3 is displayed in Fig. 3.3. 
for the 50 mM serum-free experiment.  This sequence of 30 sec time segments shows 
the increased activity ignored in Fig. 3.3.  Burst rates rise temporarily form 36 bpm in 
the reference state, to 42 bpm 2 min after application and reach 78 bpm at 100 min.  
The activity decreases thereafter. The IT50 level activity shown in Fig. 3.3 D reveals that 
the decay in bursting is dominated by an increase in burst period as well as by a 














































Fig. 3.3. Change in network pattern after 50 mM ADA. Burst rate increases for 50 
minutes before decreasing from reference activity range. (A) Raster display of reference 
spike activity, disinhibited by 40 mM bicuculline. (B) Decrease in period between 
population bursts 1 minute after 50 mM ADA application. (C) 100 minutes post ADA 
application showing a continued decrease in spike period without loss of burst 
coordination. (D) Raster spike display at the IT50. (E) 5 hr after the ADA application.  
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3.1.2 ADA Dose Responses 
Low concentration titrations (3 mM ADA) show no immediate effect in reference 
spike activity until 24 mM. A decrease in active units is not observed until 45 mM. Two 
full medium changes could not recover spike activity. The observed EC50 for an instant 
effect in spike rate from reference after application was 30 mM ADA. 
 
Fig. 3.4. Dose response for ADA on a single culture disinhibited with 40 mM bicuculline. 
(A) Titrations with 3 mM ADA until the total concentration of 54 mM (18 titrations). Activity 
loss was irreversible with two medium changes. decrease in spike activity as a function 
of ADA concentration. The observed IC50 was: 38 mM ADA, and TC50: was 48 mM (B) 
Percent decrease from reference spike activity is on the y axis and the concentration 




3.1.3 Morphological Responses 
The time lapse microscopy of ADA experiments exhibited a granular cytoplasm 
and beading of processes, known as Wallerian degeneration See Fig. 3.5 A and D for 
the loss of an axon, granulation of the glial carpet, and retraction of the soma from and 
ovoid shape to a circular one. In the absence of specific staining, axons cannot always 
be visually identified.  However, in all ADA time lapse microscopy, processes extending 
from cell bodies, would bead and disappear in a time period (n=3).  
 
Fig. 3.5. Morphological responses to 50 mM ADA. (A) Directly after dose.  White arrow 
identifies axon. (B) 30 minutes after dose, axon is showing signs of Wallerian 
degeneration (see insert). (C) Axon has degenerated, leaving debris. (D) Axon debris is 
gone, full tissue retraction and soma shape changes. The white arrow displayed stays 




 Acrolein Stabilized in 10% Hydroquinone (AHQ) 
All data on acrolein in 10% HQ is preliminary data. Due to an ongoing 
backorder, this chemical was unattainable from Sigma Aldrich or Fisher scientific 
through the period of July 2017-January 2018, when the lab protocol expired and 
cell culture was permanently closed down. The original July order was cancelled 
in November 2017 when it was stated by the company that they could not 
guarantee the shipment of this chemical in the foreseeable future. At this time, 
the analytical source acrolein became backordered as well. 













MA016 60 30 4.26.16 6.1.16 67 
MA017 1,100 21 4.26.26 6.8.16 74 
MA018 213 45 4.26.16 6.16.16 82 
MA021 2580 17 4.26.16 6.28.16 90 
MB021 13200 10 4.26.16 6.28.16 90 
MA022 50 22 6.28.16 8.3.16 36 
MA019 3,000 Histology 6.28.16 7.27.16 28 
MA020 50 Histology 6.28.16 7.28.17 29 
 
3.2.1 AHQ Dose Response 
AHQ exhibited a relationship between time and concentration. For 
concentrations < 2 mM a biphasic profile was observed. First phase: increase in 
spike activity, followed by a decrease to 100% in spike activity. In concentrations 
> 2 mM, there rapid loss of activity.  
One hundred percent activity loss from reference plotted against AHQ 
concentration reveals a relationship (in comparable medium), there is a sigmoidal 
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relationship. The linear segment of the sigmoidal curve has the concentrations 
0.5 - 2.0 mM.  
 
Fig. 3.6. Response in percent change of spike activity from reference after application of 
AHQ. (A) Lower concentrations exhibit a biphasic response profile. The first profile is an 
increase in spike rate from reference, followed by a decrease in spike rate and then a 
decrease in active channels. AHQ concentrations at 2mM cause an instantaneous 
decrease in spike activity as well as active channels. (B) AHQ concentration is plotted 
against time until 100% activity loss in experiment that did not contain serum.  
 
After low concentrations of AHQ were applied into network medium, a biphasic 
response was seen. The first phase began with an increase in spike activity that was 
followed by a 100% decrease in spike rate. 
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When 5% serum was added to one experiment, there was no biphasic response 
profile. The exact same AHQ concentration with serum had a very different profile (Fig. 
3.7). 
 
Fig. 3.7. Decrease in spontaneous activity measured as percent of reference overtime 
for two 50 mM AHQ experiments: one in medium with serum and the other in serum free 
medium. The IT50 with the presence of serum is 350 min, without serum it is 1,200 min    
 
3.2.2 Changes in Network Spike Patterns 
 Immediately after application, population burst rate increased rapidly and 
continued to increase during this phase profile. Periods of increased population bursts 
would dominate the first phase. New units would appear on the oscilloscope that had 
not been above noise levels prior to application. 
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 At 1.1 mM AHQ, this same profile was observed over a period of 10.0 min. The 
coordination is sustained until total spike activity is below 90% reference activity. At this 
point, all activity is lost, and unable to be revived by a medium change. The death 
profile is either reduction in ignition sites or neural ignition failure. 
 
Fig. 3.8. Network spike production and patterns change after 60 mM AHQ. (A) Raster 
display of spontaneous network spike production, disinhibited by the GABAA antagonist 
bicuculline (one-minute data segments). (B) After 60 mM AHQ dose, the burst rate 
increases with time(C) 1,000 minutes after dose:  continued inter spike period decrease. 
(D) The 300% increase of total spike activity over the 1,690 min of activity. The 
interrupted period of time (rectangle) represents amplifier shutoff for chamber 
adjustment. The circle shows a temporary decrease from a sudden osmotic shift. A 




Fig. 3.9. A 1.1 mM AHQ application after 1.0 hr of stable reference spike activity. (A) 
Raster display of reference burst activity with 40 mM bicuculline. (B) The exact time 
period of 1.1 mM AHQ application the activity increased from a spike rate of 450 
spk/min to 650 spk/min Population burst rate increases rapidly with coordination. 






Fig. 3.10. Morphological responses to 50 mM AHQ application on a frontal cortex 
network. (A) Directly after application (B) One hr after, the yellow box outlines two 
neurons with loss of processes and cytoplasmic granulation (C) Three hr after, total loss 
of processes. 
 
In Fig. 3.10, beading of cell body processes is observed in picture B. Total 
loss of all processes is observed in picture C.  
When a 10 mM dose of AHQ was given to the network, an instantaneous 
response occurred on the morphological level. Lipid protrusions of the membrane began 
exiting the glial carpet and certain areas of the processes connected to the cell body 





Fig. 3.11. A 10 mM AHQ on a frontal cortex network. (A) Right after 10mM AHQ dose. 
(B) 5 minutes after dose, lipid bubbles emanate from glia cells (white arrows. Note: 
Putative disintegration of peripheral dendrites (black arrows). 
 
 Hydroquinone (HQ) 
Hydroquinone was a stabilizer in the acrolein used in ADA and AHQ (sections 1 
& 2 of results). There is no data for toxicity of this compound on neuronal cultures.  To 
assure that HQ did not interfere with the results in that section. An HQ toxicity screening 
was conducted for pattern responses in a separate series of experiments. Networks 
were exposed to 0.1 mM HQ in the 50 mM AHQ experiments.  
In the following data, HQ was found to have no effect on network activity in 
applications lower than 150 mM. However, HQ did show toxicity with a TD50 value of 8.6 
mM and IC50 of 3.5 mM.  It also generated instability by inducing intense bursting and 
showed high and persistent rebound activity after medium changes. For HQ 
experiments under bicuculline, there were no functional effects until 3.5 mM.  The  
experiments were run with both native networks as well as disinhibited networks with 40 





















MA030 5 0.032 10 07.18.17 09.07.17 57 
MB030 2.25 0.0175 21 07.18.17 09.07.17 57 
MB033  25 0.4 37 10.10.17 11.16.17 35 
MA035A 150 1.35 55 10.10.17 11.30.17 49 
MB035A 600 1.8 43 10.10.17 11.30.17 49 
MA035B 750 7.95 55 10.10.17 11.31.17 50 
MB035B 1200 16.08 43 10.10.17 11.31.17 50 
MA036 1000 14 18 10.24.17 12.01.17 60 
 
3.3.1 Responses to Low HQ Concentrations 
There was no observable effect to 25 mM titrations of HQ up to 400 mM, until receiving a 
medium change to a medium of identical osmolarlity and pH, without HQ (n=6). The 
responses were characterized by a massive increase in spike rate that increased the 
level reference activity with oscillations of super bursting (Suri, master’s thesis).  
Network pattern changes occurred immediately after medium change. There was 
an immediate change to coordinated bursting that mimicked the burst pattern of a 
disinhibited culture. 
 Applications in ranges ≥ 150 mM HQ exhibit an inhibitory response profile. The 
inhibition could not be quantified by concentration because applications ranging from 
150 mM to 1,800 mM HQ showed the same decrease to minimal activity. However, 
medium changes induced 400-800% greater activity than reference. The response 
profile of dramatically increased activity at the time of medium change would last 6-8 
hours and be followed by a period of oscillating inhibition (n=3). A second medium 
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change 12 hours after the first medium change brought reference spike activity back to 
normal with the same number of active channels (n=1) (Fig. 3.13). 
 
Fig. 3.12. Network changes to multiple additions of HQ. (A) HQ titration from 25 mM – 
400 mM. No response in spike rate until a medium change. Rapid increase in spike rate 
by 400 %( B) Nex roster display of real time spiking shows no pattern changes before 
(1) and after HQ application (2). Immediately upon removal of HQ by medium change 
(3), there was a strong change is spike patterns that lasted until a second medium 
change 12 hours later. (4) 10 min after medium change, (5) 2 hr after medium change. 
(6) 4 hr. after medium change. 
 
 This response profile of increased activity was distinguished by the re-addition of 
hydroquinone into the network. After being distinguished, it can be induced again by 





Fig. 3.13. Applications  ≥ 150 mM HQ show a decrease in spike rate. This is completely 
reversible with a medium change and induces a large increase in spike rate and 
decrease in period between spikes. Network pattern change is reproducible and 
extinguishable in the same experiment.    
 
3.3.2 Dose Response Curves 
Because of the inhibitory response of HQ, 40 mM bicuculline stabilized network 
activity to quantify its toxicity. Once disinhibited, titrations of HQ showed spike activity 
decreased at 750 mM with a functional IC50 of 1,800 mM and active channels decreased 
at 5 mM with an LC50 of 8.5 mM HQ. 
Response profile between a native network and a disinhibited network were 
dramatically different. Active channels were used to quantify this shift in response to 
HQ. When plotted with HQ concentration as the dependent variable, the IC50 for a 






Fig. 3.14. Dose response curve representing all hydroquinone experiments under 40 mM 
bicuculline (n=6). Dose response curve from all HQ experiment under 40 mM GABA A 
antagonist. IC50 value is 3.5 mM (pooled data from n=5).  
 
 Analytical Acrolein (AA) 













MA024 100 40 06.06.17 06.29.17  29 
MB024 500 52 06.06.17 06.29.17  29 
MB025 85 21 06.06.17 07.04.17  35 
MA025 75 50 07.14.17 06.09.17 36  
MA028 18.5 27 07.14.17 09.17.17  91 
MB028 18.5 22 07.14.17 09.17.17  91 
MB029 18.5 55 07.14.17 09.09.17  83 
MA031 18 42 10.10.17 11.09.17  29 
MB031 18 45 10.10.17 11.09.17  29 
 
3.4.1 Network Response Profiles 
Analytical acrolein exhibited a biphasic profile at lethal and nonlethal 
concentrations. At 30 mM and less, there was no loss in reference activity observed in a 
6-day period after application but there was a change in reference spike activity and 
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patterns that never returned to reference. In one experiment, the change was 
extinguished with bicuculline 48 hr after 30 mM bicuculline (Fig. 3.18). As concentration 
increases, time until 100% activity loss decreases. 
 
Fig. 3.15. Network activity responses to single analytical acrolein applications in the mM 
range. Linear plots represent concentration dependent responses. 50 mM, responds 
with biphasic profile before 100% loss in activity. 30 mM and below (n=3) respond in a 
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Fig. 3.16. Network activity responses to single analytical acrolein applications in the mM 
range. In concentration < 1 mM, a biphasic response profile is observed before 100% 
loss in spike activity. 
 
 A linear log-log relationship exists between concentration and time for 100% 
activity loss. The lower concentrations would be expected to be nonlethal because is a 
pro-inflammatory compound found inside of mammalian tissue systems in periods of 





Fig. 3.17. Dose response curve for analytical acrolein. Low concentrations have no 
effect on loss of activity from reference. As the concentration gets higher the time until 
100% loss of activity decreases. 
 
3.4.2 Spike Production and Pattern Changes 
Analytical acrolein was the first of the compounds to be examined without 
bicuculline. The spike production and pattern changes that occurred in these 
experiments were an increase in burst population rate and coordination. During the 
second response profile of population burst decrease, coordination is sustained until 
































Fig. 3.18. A 30 mM application of analytical acrolein to a network after 2.5 hr of stable 
reference activity. Network spike production and patterns destabilize and increase for 
48 hours until 40 mM bicuculline application at T= + 49 hr. (A) Raster display of 
reference spike activity of a spontaneously firing network. This was the average activity 
for the 2.5 hr reference period. (B) Instant change in network spiking after 30 mM 
application. (C) T= 1 min after, increased burst rate and coordination (D)-(I) continued 




At nonlethal concentrations, pattern changes still occurred that did not return to 
reference activity in the 6 d observation period (n=2, at 20 mM AA). The pattern change 
was characterized by an increased population burst rate and coordination. The Spike 
activity display shows a dramatic increase in the range of total spikes per minute or 
paroxysmal superbursting. Changes in spike patterns between bicuculline-like bursting 
and burst packets were observed.  The latter increased in width over time. A surprising 
observation was the pattern stabilization with an addition of bicuculline (see Fig. 3.18).  
Higher concentrations, less than 1 mM, had the same response profile of 
increased burst rate and coordination. This was followed by a death profile of decreased 
burst rate with sustained coordination until total loss of activity. Fig. 3.19 demonstrates 
the raster display of this biphasic response. 
 
Fig. 3.19. A 0.5 mM analytical acrolein application after 2.5 hr of stable reference 
activity. (A) native reference activity. (B) application increases burst population rate and 
coordination. (C-E) the rate of population bursts decreases from 108 bpm to 16 bpm. 




Once analytical acrolein is applied into the network, spontaneous reference spike 
activity immediately increases, and gains coordination shortly thereafter. This 
coordination is maintained when the burst rate begins to decrease. This same profile is 
seen concentrations ranging from 50 mM -0.5 mM.  The observed death profile is that of 
either reduction in ignition sites or neural ignition failure (Ham et al., 2008). Very few 
channels fire outside of the bursts which have full participation.  
 
 
Fig. 3.20. A 50 mM application of analytical acrolein to a spontaneously firing network. 
(Top) Individual channel spike activity for 3 segments of Plexon data. The Y axis is total 
spikes per minute generated by a channel and the x axis is time in minutes. (Bottom) 
Total spike activity for the entire network. After a 50 mM application, some channels 
have an inhibitory profile while other an excitatory until total loss in activity. 
 
3.4.3 Waveshape Analysis 
Wave shapes were recorded by Plexon with timestamps (µSec) that can be 
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extracted in order to display wave shapes for certain reference periods within the 
experiment. Because the wave shapes would visible grow on the Plexon channel 
display window after acrolein application, the waveshapes were analyzed further.  
In analyzed wave shapes, a 25-35% increase in amplitude is observed (Fig. 
3.21). In applications of small concentrations, experiment protocols report new wave 
shapes appearing in the channel selection after application. The narrowing of the peaks 
paired with increased amplitude are common observations when there is a shift in Na+ 
permeability. 
 
Fig. 3.21. A 20 and 30 mM analytical acrolein application increases the action potential 




 Summation of Acrolein Data  
The summation of acrolein data on a single graph shows a relationship between 
each compound and the time until 100% activity loss is plotted in Fig. 3.22. At 400 mM, 
the respective IT100 values are 6 minutes for analytical acrolein, 12 minutes for AHQ, 
and 28 minutes for ADA. The decreased IT100 value would be expected for analytical 
acrolein, which has no stabilizer present.  
 
Fig. 3.22. All acrolein compounds used in results section prior are summated. Only 
lethal concentrations are used in this data set. ADA and AHQ have 40 mM bicuculline, 





























ADA AcroleinHQ Analytical Acrolein
At 400 uM,  IT(100) values are:  





Analytical acrolein experiments did not achieve the desired iterations due to a 
supplier shortage. The applications with analytical acrolein did not have bicuculline for 
stabilization but retained the same observed responses as ADA and AHQ (which 
contained 40 mM bicuculline). Analytical acrolein had the lowest IT100 values, which 
would be expected of an autooxidant that is not stabilized. 
For all three compounds: a biphasic response is observed beginning with a 
period of increased population burst rate. In experiments with 40 mM bicuculline, 
coordination was present in the reference and maintained. In the analytical acrolein 
applications (without bicuculline), coordination would appear after a 5.0-10.0 sec period 
of abnormally high, full network spiking. The increase in population burst rate was 
observed in each acrolein compound that was tested, except at very high 
concentrations when rapid activity loss dominated the initial increase of activity and 
those with 5% serum.  
The second phase is characterized by a decrease in population burst rate with 
sustained coordination until 100% activity loss for all three compounds. Burst durations 
and spikes in bursts also decreased, contributing to the loss of activity with time.  
The paradoxical effect of acrolein, an increased potency in the presence of 
serum, was observed in ADA and AHQ (see Figs 4 & 10). Acrolein has been shown to 
react with many systemic proteins via the Mailard reaction. These reaction products 
cause apoptosis and necrosis in cell culture (Conklin et al., 2012). Reaction products 
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have not yet been studied in functional networks but may be toxic by interacting with 
membrane receptors and channels that control spike production. 
One mechanism for the initial increase in activity in acrolein experiments is 
spermine, a free radical scavenger. Free concentrations of spermine decrease once 
acrolein has been generated endogenously because of adduction to free radicals and 
acrolein (Ha et al., 1998; Tsuisui et al., 2016). In normal mM concentrations, spermine 
has little effect on NMDA receptor/channel complex or voltage gates Na+ channels. 
Upon shifting to low levels in the range of 1.0-10 mM, there is an increase in NMDA 
channel opening frequency in primary cortical cultures (Rock & Macdonald, 1992).  
Other important cellular defenses against electrophilic compounds, such as 
glutathione transferase, become depleted rapidly after the generation of acrolein (Shi et 
al., 2011). In patients with kidney disease, there is a depletion in spermine levels from 
serum. Putrescine, polyamine oxidase and acrolein are increased during this period 
(Igarashi et al, 2006). Acrolein is continuously generated by spermine oxidase, which 
serves to deplete spermine levels (Igarashi et al., 2011). 
Waveshape data shows an increase in peak to peak amplitude in the three 
experiments that have been examined (Fig. 3.21). Shifts in Na+ permeability increases 
the action potential peak to peak amplitude. Spermine depletion to low concentrations 
influences Na+ channels leading to an increase in spontaneous spiking and hyper-
synchronized discharge in cortical neurons (Fleidervish et al., 2008). This is a 
mechanism that should be researched further, as AP amplitude increases can enhance 
exocytosis and network excitation. 
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Fig. 4.1 depicts a 30 mM application of analytical acrolein that induced an 
increase in population burst rate with coordination over 48 hours. This increased burst 
rate was extinguished by the addition of 40 uM bicuculline. There is no explanation for 
this response to a GABAA antagonist. 
 
Fig. 4.1. A network response to a 30 mM application of analytical acrolein. The upper 
Vernac display is the entire 50 hr. recording. A-D: network activity with correlated 15 sec 
spike raster plots.  The bottom panel shows the activity transition from a 40 mM 
bicuculline application (48 hours after acrolein). (A) Reference network activity. (B) One 
minute after application. (C) Twenty-eight hr. after application, sudden transition to 
paroxysmal bursting with appearance of burst packets. (D) A 40 mM bicuculline 
application decreases population burst rate while maintaining coordination. Total 





 Because HQ is a stabilizer for ADA and AHQ, a toxicity screening was necessary 
to determine independent pharmacological influences of HQ.  The final concentration of 
HQ in the medium bath of ADA and AHQ experiments is listed in Table 4.1. These bath 
concentrations are far below the concentrations that have shown independent activity 
changes (Fig. 3.12).  In the presence of 40 mM bicuculline, HQ generates no 
measurable spike rate changes until 2.5 mM (2,500 mM).   
Table 4.1. Final HQ Concentration in Acrolein Experiments 
10 mM ADA 0.00608 mM HQ 
1,000 mM ADA 0.06080 mM HQ 
1,000,000 mM ADA 60.800 mM HQ 
10 mM AHQ 0.01904 mM HQ 
1,000 mM AHQ 1.90400 mM HQ 
2,000 mM AHQ 3.80800 mM HQ 
 
At concentrations of 30 mM - 2,000 mM HQ, a medium change induces a 400-
800% increase in activity with superbursting. This network pattern change has been 
seen as late as 6 hours after medium change.  
 
 Conclusion 
If post TBI-induced excitotoxicity was only a manifestation of excess glutamate in 
the synapse, then NMDA, ampa, and kainite receptor antagonists should show success 
in treatment of secondary damage (Ikonomidou, 2002; Shohami et al., 2014). The 
literature has shown that it does not.  
Cebak et al., 2016 found that phenylalazine, a free radical scavenger, not only 
successfully mitigated acrolein formation, but attenuated mitochondrial respiratory 
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dysfunction in a mouse TBI model. Along with the continued study of functional changes 
that arise from acrolein in a spontaneously firing network, the functional toxicity for 
hydralazine and phenylalazine applications should be reviewed as well. 
Changes in polyamine levels after traumatic brain injury should also be 
investigated further. Polyamines are essential for eukaryotic growth and development. 
Deregulation in polyamines is associated with many diseased states (Minois et al, 
2011). Polyamines are also important in regulation of glutamate receptor ion channels, 
inwardly rectifying K+ channels, and other channels that affect intracellular calcium 
signaling or Na+ transport (Dingledine et al., 1999; Stanfield & Sutcliffe, 2003). If there is 
a change in the polyamines after TBI and acrolein generation, this is another avenue of 
exploration for pharmaceutical intervention. 
This study characterized how acrolein induces but also terminates spike 
production when applied to spontaneously firing cortical networks. There is no current 
literature about the functional toxicity of cortical neuronal networks to acrolein, even 
though it has been shown to enhance and prolong secondary damage in TBI (Cebak et 
al., 2016). Acrolein and its functional responses should be researched further for 







AHQ—Acrolein stabilized in 10% hydroquinone 
 
AO – Amine oxidase: and enzyme responsible for catalyzing the formation of 
polyamines 
 
ADA—Acrolein diethyl acetate 
 
Bicuculline—GABAA antagonist. Disinhibits network at 40 mM. 
 
Active channels—Channels with ten or more spikes per minute 
 
CNNS – Center for Network Neuroscience 
 
D1SGH – Dextrose-1 Sucrose Glucose Hepes: buffer solution with balanced ions for 
biological tissue 
 
DIV – Days in vitro 
 
DMEM – Dulbecco’s modified medium: nutritional solution for cell culture 
HQ—Hydroquinone, a reducing agent  
 
IC50 – Concentration that causes 50% inhibition in spikes/min 
 
IC100 -- Concentration that causes 100% inhibition in spikes/min 
 
IT100 – Time until 100% inhibition after the application of a compound at X concentration 
 
NMDA receptor – N-methyl-D-arspartate receptor: an excitatory receptor, commonly 
activated by glutamate 
 
MC—Medium change. Medium is carefully aspirated via a syringe and then replaced by 
a new medium of the same osmolarity and pH. 
 
MEA – Micro electrode array: the recording area consisting of many substrate-
integrated microelectrodes for simultaneous, extracellular recording from many sites in 
a network.   
 





ROS – Reactive oxygen species: A chemical species which is highly reactive and 
contains an oxygen atom 
 
T – Time: time in minutes 
 
TC50 – Toxic concentration for 50% of the channels 
 
TBI – Traumatic brain injury: an insult to the brain caused by external physical force 
 
Titration – a single application given in a series of applications to elucidate a dose 
response 
 
Total spikes per min: Total spikes produced each minute by individual units 
 
Serum—Donor horse serum that is heat deactivated by proprietary source as well as 
within the lab. 
 
SO – Spermine oxidase: an enzyme responsible for catalyzing the formation of 
spermine. 
 





SOLUTION SOURCE CONCENTRATION CALCULATIONS
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Acrolein Diethyl acetate (stabilized in 4% hydroquinone) (ADA) Solutions 
Source solution: 0.854 g / ml, 25.0 ml volume 
0.854 x 1000 ml = 854 g / L 
854 g / MW 130.18 = 6.57 M ADA Source 
 
Acrolein (stabilized in 10% hydroquinone) (AHQ) Solutions 
Source solution: 0.839 g / ml, 25.0 ml volume 
0.839 x 1000 ml = 839 g / L 
839 / MW 56.06 = 14.97 M AHQ Source 
 
Analytical Acrolein Solutions 
Source solution: 0.839 g / ml, 25.0 ml volume 
0.839 x 1000 ml = 839 g / L 
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